MedMira Inc. (MIR.V)
CAD 0.08
(-5.88%)
CAD 0.08
(-5.88%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 182.42 Thousand CAD | -9.67% |
| 2022 | 201.96 Thousand CAD | -14.34% |
| 2021 | 235.77 Thousand CAD | 5.92% |
| 2020 | 222.58 Thousand CAD | 109.49% |
| 2019 | 106.25 Thousand CAD | -41.68% |
| 2018 | 182.19 Thousand CAD | -19.74% |
| 2017 | 227 Thousand CAD | -22.65% |
| 2016 | 293.45 Thousand CAD | -2.16% |
| 2015 | 299.92 Thousand CAD | -0.61% |
| 2014 | 301.77 Thousand CAD | 47.2% |
| 2013 | 205 Thousand CAD | -9.23% |
| 2012 | 225.85 Thousand CAD | 5.24% |
| 2011 | 214.6 Thousand CAD | -40.33% |
| 2010 | 359.64 Thousand CAD | 15.41% |
| 2009 | 311.61 Thousand CAD | -33.77% |
| 2008 | 470.5 Thousand CAD | -3.35% |
| 2007 | 486.83 Thousand CAD | -30.76% |
| 2006 | 703.07 Thousand CAD | 31.11% |
| 2005 | 536.26 Thousand CAD | -32.48% |
| 2004 | 794.22 Thousand CAD | 25.89% |
| 2003 | 630.9 Thousand CAD | -24.72% |
| 2002 | 838.12 Thousand CAD | -30.75% |
| 2001 | 1.21 Million CAD | -30.48% |
| 2000 | 1.74 Million CAD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 212.39 Thousand CAD | 20.34% |
| 2024 Q1 | 176.49 Thousand CAD | -3.25% |
| 2024 Q3 | 207.08 Thousand CAD | -2.5% |
| 2023 Q2 | 184.68 Thousand CAD | -4.18% |
| 2023 FY | 182.42 Thousand CAD | -9.67% |
| 2023 Q1 | 192.73 Thousand CAD | -4.57% |
| 2023 Q4 | 182.42 Thousand CAD | 2.12% |
| 2023 Q3 | 178.64 Thousand CAD | -3.27% |
| 2022 Q2 | 218.32 Thousand CAD | -2.53% |
| 2022 Q4 | 201.96 Thousand CAD | -14.21% |
| 2022 Q1 | 224 Thousand CAD | -4.99% |
| 2022 FY | 201.96 Thousand CAD | -14.34% |
| 2022 Q3 | 235.42 Thousand CAD | 7.83% |
| 2021 Q1 | 339.48 Thousand CAD | 52.52% |
| 2021 Q2 | 290.79 Thousand CAD | -14.34% |
| 2021 FY | 235.77 Thousand CAD | 5.92% |
| 2021 Q3 | 251.63 Thousand CAD | -13.47% |
| 2021 Q4 | 235.77 Thousand CAD | -6.3% |
| 2020 Q1 | 103.96 Thousand CAD | -2.15% |
| 2020 Q2 | 101.75 Thousand CAD | -2.13% |
| 2020 Q3 | 110.08 Thousand CAD | 8.19% |
| 2020 Q4 | 222.58 Thousand CAD | 102.2% |
| 2020 FY | 222.58 Thousand CAD | 109.49% |
| 2019 FY | 106.25 Thousand CAD | -41.68% |
| 2019 Q4 | 106.25 Thousand CAD | -37.73% |
| 2019 Q3 | 170.62 Thousand CAD | -6.07% |
| 2019 Q2 | 181.65 Thousand CAD | -0.42% |
| 2019 Q1 | 182.41 Thousand CAD | 0.12% |
| 2018 Q4 | 182.19 Thousand CAD | -10.61% |
| 2018 FY | 182.19 Thousand CAD | -19.74% |
| 2018 Q1 | 211.24 Thousand CAD | -6.94% |
| 2018 Q2 | 210.54 Thousand CAD | -0.33% |
| 2018 Q3 | 203.82 Thousand CAD | -3.19% |
| 2017 Q4 | 227 Thousand CAD | -10.62% |
| 2017 Q2 | 280.85 Thousand CAD | -1.44% |
| 2017 Q1 | 284.96 Thousand CAD | -2.89% |
| 2017 Q3 | 253.97 Thousand CAD | -9.57% |
| 2017 FY | 227 Thousand CAD | -22.65% |
| 2016 Q4 | 293.45 Thousand CAD | -12.11% |
| 2016 FY | 293.45 Thousand CAD | -2.16% |
| 2016 Q3 | 333.89 Thousand CAD | 3.99% |
| 2016 Q2 | 321.09 Thousand CAD | 6.67% |
| 2016 Q1 | 301.01 Thousand CAD | 0.36% |
| 2015 FY | 299.92 Thousand CAD | -0.61% |
| 2015 Q3 | 279.7 Thousand CAD | -21.17% |
| 2015 Q4 | 299.92 Thousand CAD | 7.23% |
| 2015 Q1 | 298.46 Thousand CAD | -1.09% |
| 2015 Q2 | 354.84 Thousand CAD | 18.89% |
| 2014 Q4 | 301.77 Thousand CAD | 19.64% |
| 2014 Q1 | 233.81 Thousand CAD | 14.06% |
| 2014 FY | 301.77 Thousand CAD | 47.2% |
| 2014 Q2 | 289.89 Thousand CAD | 23.98% |
| 2014 Q3 | 252.22 Thousand CAD | -12.99% |
| 2013 Q3 | 164.57 Thousand CAD | -29.68% |
| 2013 Q1 | 231.89 Thousand CAD | 2.67% |
| 2013 FY | 205 Thousand CAD | -9.23% |
| 2013 Q4 | 205 Thousand CAD | 24.57% |
| 2013 Q2 | 234.01 Thousand CAD | 0.92% |
| 2012 Q1 | 238.63 Thousand CAD | 11.2% |
| 2012 Q3 | 253.11 Thousand CAD | -3.67% |
| 2012 FY | 225.85 Thousand CAD | 5.24% |
| 2012 Q4 | 225.85 Thousand CAD | -10.77% |
| 2012 Q2 | 262.76 Thousand CAD | 10.11% |
| 2011 Q2 | 367.33 Thousand CAD | -7.91% |
| 2011 Q1 | 398.88 Thousand CAD | 10.91% |
| 2011 Q3 | 327.51 Thousand CAD | -10.84% |
| 2011 Q4 | 214.6 Thousand CAD | -34.48% |
| 2011 FY | 214.6 Thousand CAD | -40.33% |
| 2010 FY | 359.64 Thousand CAD | 15.41% |
| 2010 Q1 | 275.01 Thousand CAD | -11.75% |
| 2010 Q2 | 324.99 Thousand CAD | 18.18% |
| 2010 Q3 | 284.26 Thousand CAD | -12.53% |
| 2010 Q4 | 359.64 Thousand CAD | 26.51% |
| 2009 Q1 | 431.24 Thousand CAD | -8.35% |
| 2009 Q2 | 413.45 Thousand CAD | -4.12% |
| 2009 Q3 | 403.85 Thousand CAD | -2.32% |
| 2009 Q4 | 311.61 Thousand CAD | -22.84% |
| 2009 FY | 311.61 Thousand CAD | -33.77% |
| 2008 Q1 | 434.68 Thousand CAD | -10.71% |
| 2008 FY | 470.5 Thousand CAD | -3.35% |
| 2008 Q4 | 470.5 Thousand CAD | 11.07% |
| 2008 Q3 | 423.61 Thousand CAD | -2.12% |
| 2008 Q2 | 432.8 Thousand CAD | -0.43% |
| 2007 FY | 486.83 Thousand CAD | -30.76% |
| 2007 Q1 | 648.42 Thousand CAD | -7.77% |
| 2007 Q3 | 505.83 Thousand CAD | -13.43% |
| 2007 Q4 | 486.83 Thousand CAD | -3.76% |
| 2007 Q2 | 584.32 Thousand CAD | -9.89% |
| 2006 FY | 703.07 Thousand CAD | 31.11% |
| 2006 Q4 | 703.07 Thousand CAD | 1.35% |
| 2006 Q3 | 693.73 Thousand CAD | 26.92% |
| 2006 Q1 | 676.52 Thousand CAD | 26.16% |
| 2006 Q2 | 546.6 Thousand CAD | -19.2% |
| 2005 Q4 | 536.26 Thousand CAD | -3.74% |
| 2005 FY | 536.26 Thousand CAD | -32.48% |
| 2005 Q1 | 655.79 Thousand CAD | -17.43% |
| 2005 Q2 | 637.83 Thousand CAD | -2.74% |
| 2005 Q3 | 557.12 Thousand CAD | -12.65% |
| 2004 Q1 | 752.25 Thousand CAD | 19.24% |
| 2004 FY | 794.22 Thousand CAD | 25.89% |
| 2004 Q3 | 619.67 Thousand CAD | -12.74% |
| 2004 Q4 | 794.22 Thousand CAD | 28.17% |
| 2004 Q2 | 710.13 Thousand CAD | -5.6% |
| 2003 Q3 | 648.99 Thousand CAD | -25.09% |
| 2003 Q1 | 816.68 Thousand CAD | -2.56% |
| 2003 FY | 630.9 Thousand CAD | -24.72% |
| 2003 Q2 | 866.32 Thousand CAD | 6.08% |
| 2003 Q4 | 630.9 Thousand CAD | -2.79% |
| 2002 Q3 | 1.2 Million CAD | 1.59% |
| 2002 FY | 838.12 Thousand CAD | -30.75% |
| 2002 Q2 | 1.18 Million CAD | -0.09% |
| 2002 Q4 | 838.12 Thousand CAD | -30.26% |
| 2002 Q1 | 1.18 Million CAD | 0.0% |
| 2001 FY | 1.21 Million CAD | -30.48% |
| 2000 FY | 1.74 Million CAD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Arch Biopartners Inc. | - CAD | -Infinity% |
| Covalon Technologies Ltd. | 5.94 Million CAD | 96.931% |
| Hemostemix Inc. | - CAD | -Infinity% |
| Universal Ibogaine Inc. | - CAD | -Infinity% |
| Kane Biotech Inc. | 250.41 Thousand CAD | 27.152% |
| Marvel Biosciences Corp. | - CAD | -Infinity% |
| NervGen Pharma Corp. | - CAD | -Infinity% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |